Skip to content
GLP-1 Savers
Menu

Head-to-head · Value Score

CoreAge Rx vs AM Rx

Two GLP-1 deals, scored on the same six factors. CoreAge Rx lands a Value Score of 93, AM Rx a 55. Here's who gives you the honest lower price — and where each one bites back.

★ Better value

CoreAge Rx

#1 · Grade A+ · Best Value

Est. first month

$149/mo

Save ~89% vs brand-name
Get this deal Full CoreAge Rx review →
VS

AM Rx

#373 · Grade C · Watch List

Est. first month

From $151/mo (quarterly plan, plus a separate fee, compounded)

Save ~89% vs brand-name
Get this deal Full AM Rx review →

The verdict

Better value: CoreAge Rx

CoreAge Rx takes it on Value Score, 93 to 55 an est. $149/mo first month, with no teaser step-up baked in. AM Rx isn't out of it: Patients with insurance seeking brand-name GLP-1 access (review regulatory warnings carefully).

CoreAge Rx is also our overall #1 pick across the whole deals board — a flat, all-in price on both molecules in all 50 states. That's why it wins here on the score, not just this matchup.

Deal-by-deal

The numbers that decide it. Green ✓ marks the stronger side on each line.

DealCoreAge RxAM Rx
Value Score93 (A+)55 (C)
Est. first month$149/moFrom $151/mo (quarterly plan, plus a separate fee, compounded)
Save vs brand-name~89%~89%
Semaglutide$149/moFrom $151/mo (quarterly plan, plus a separate fee, compounded)
Tirzepatide$349/moNot disclosed
Both moleculesYesNo
PricingFlat — no step-upWatch
CoverageAll 50 statesCoverage not published

Factor by factor

The six factors behind each Value Score. The orange bar marks the stronger side. See the methodology.

88
Lowest Real Price
82
CoreAge Rx: 88. AM Rx: 82.
98
No Teaser-Rate Bait
28
CoreAge Rx: 98. AM Rx: 28.
98
Nationwide Availability
45
CoreAge Rx: 98. AM Rx: 45.
95
Both Molecules
62
CoreAge Rx: 95. AM Rx: 62.
95
Easy Cancellation
44
CoreAge Rx: 95. AM Rx: 44.
84
Reputation
25
CoreAge Rx: 84. AM Rx: 25.

CoreAge Rx

The honest lowest price: both molecules at one flat, all-in monthly rate that never steps up after month one.

Why it's a deal

  • Flat, all-in monthly price with no intro-rate step-ups after month one
  • Both compounded semaglutide and tirzepatide on one account
  • Available in all 50 states
  • Straightforward, low-friction cancellation — no lock-in

The fine print

  • Not the rock-bottom sticker — a couple of teaser tiers advertise lower month-one rates
  • No FDA-approved brand-name option (compounded only)
  • Does not yet publicly name its 503A/B pharmacy partner

AM Rx

AM Rx (getamrx.com) is a telehealth platform operated by FitRX, LLC (also operates Zealthy and FitRx).

Why it's a deal

  • Insurance coordination for brand-name GLP-1s — as low as $25/mo
  • All four major brand-name GLP-1s available (Ozempic, Wegovy, Zepbound, Mounjaro)
  • HSA and FSA accepted
  • Video visits available with providers averaging 10+ years' experience
  • Compounded semaglutide from $151/mo on the quarterly plan

The fine print

  • Active FTC/DOJ lawsuit over deceptive billing and subscription practices
  • Novo Nordisk false-advertising lawsuit (Aug 2025)
  • Parent company Zealthy holds a BBB D- rating with 2,370+ complaints
  • Trustpilot 2.0/5, with 85% one-star reviews citing billing disputes and unreachable support
  • FDA has issued this company a warning letter; the letter is public in FDA's warning-letter database
Get the CoreAge Rx deal Get the AM Rx deal

Assume any provider we list may compensate us — we may earn a commission, at no cost to you. It never changes a Value Score.

Neither one the right fit? Every program that outscores CoreAge Rx is ranked on the CoreAge Rx alternatives board, and the same list for the other side is on alternatives to AM Rx.

More head-to-heads

← All comparisons

Prices, states and verification reflect each program's public disclosures at last check; the Value Score is our editorial judgment per the methodology. “Save vs brand-name” compares the lowest disclosed monthly price against a ~$1,349/mo brand-name cash reference. Prices change — confirm on each provider's site. Not medical advice; see our disclosure.